


# Pediatric COVID-19 Vaccine Updates

Maine Immunization Program

June 30, 2022



# Agenda

- Vaccine Schedule
- Product Labeling
- Age Allowances
- Interchangeability
- Miscellaneous Updates
- Questions

# Disclaimer

All information in this presentation is subject to change.  
Information shared in these slides are assumptions  
as of 6/30/2022.

# Pfizer-BioNTech Pediatric Schedule: People Who Are NOT Moderately or Severely Immunocompromised

**Pfizer-BioNTech**  
(6 months–  
4 years)



0.2 mL (3 mcg)

**Pfizer-BioNTech**  
(5–11 years)




0.2 mL (10 mcg)

**Pfizer-BioNTech**  
(12–17 years)



0.3 mL (30 mcg)

# Pfizer-BioNTech Pediatric Schedule: People Who ARE Moderately or Severely Immunocompromised



# Moderna Pediatric Schedule: People Who Are NOT Moderately or Severely Immunocompromised

**Moderna**  
(6 months–  
5 years)



0.25 mL (25 mcg)

**Moderna**  
(6–11 years)



0.50 mL (50 mcg)

**Moderna**  
(12–17 years)



0.50 mL (100 mcg)

# Moderna Pediatric Schedule: People Who ARE Moderately or Severely Immunocompromised

**Moderna**  
(6 months–  
5 years)




0.25 mL (25 mcg)

**Moderna**  
(6–11 years)



0.50 mL (50 mcg)

**Moderna**  
(12–17 years)



0.50 mL (100 mcg)

# Moderna Boosters

Moderna is **NOT** currently approved for booster doses for individuals under 18 years of age.

- Individuals that receive a primary series of Moderna vaccine should **NOT** get a booster dose of Pfizer-BioNTech vaccine
- Individuals that receive a primary series of Pfizer-BioNTech vaccine should **NOT** get a booster dose of Moderna vaccine
  
- FDA anticipates Moderna booster doses will be approved within the next five months



# Schedule Resources

- At-a-glance schedule:

<https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-vacc-schedule-at-a-glance-508.pdf>

- Interim COVID-19 immunization schedule:

<https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf>

**AT-A-GLANCE**

**COVID-19 Vaccination Schedules**

Use the schedules below to determine how many total COVID-19 vaccine doses are recommended based on primary series product, age, and immune status. This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

**COVID-19 Vaccination Schedule for Most People**

**COVID-19 Vaccine**  
Interim COVID-19 Immunization Schedule for 6 Months of Age and Older

The table below provides guidance for COVID-19 vaccination schedules based on age and medical condition. Scheduling considerations include:

- Administer the appropriate vaccine product based on the recipient's age and the product's age indications.
- COVID-19 vaccines may be administered on the same day as other vaccines.
- Doses administered at any time after the intervals outlined below are valid.

Detailed information can be found in CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, see: [www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html)

**Table 1. Immunization Schedule for Children 6 Months through 17 Years of Age**

Type	Product*	Recipient Age	For Most People		Those Who Are Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses <sup>1</sup>	Doses	Interval Between Doses <sup>2</sup>
			Total doses: 2 doses		Total doses: 3 doses	
mRNA vaccine	Moderna (blue vial cap with messenger-banded label)	6 months through 6 years	Dose 1 to 2	At least 4-8 weeks <sup>3</sup>	Dose 1 to 2	At least 4 weeks
	PFizer BioNTech (blue vial cap with messenger-banded label)	6 months through 4 years	Dose 1 to 2	At least 3-8 weeks <sup>3</sup>	Dose 1 to 2	At least 3 weeks
	PFizer BioNTech (orange vial cap with messenger-banded label)	9 through 11 years	Dose 2 to 3	At least 8 weeks	Dose 2 to 3	At least 8 weeks
	PFizer BioNTech (purple vial cap with messenger-banded label or gray vial cap with messenger-banded label)	12 years through 17 years	Dose 1 to 2	At least 3-8 weeks <sup>3</sup>	Dose 1 to 2	At least 3 weeks
			Dose 2 to 3	At least 3 months	Dose 2 to 3	At least 3 months
			Total number: 3 doses		Total number: 4 doses	
			Dose 1 to 2	At least 3-8 weeks <sup>3</sup>	Dose 1 to 2	At least 3 weeks
			Dose 2 to 3	At least 3 months	Dose 3 to 4	At least 3 months
			Total number: 3 doses		Total number: 5 doses	
			Dose 1 to 2	At least 3-8 weeks <sup>3</sup>	Dose 1 to 2	At least 3 weeks
			Dose 2 to 3	At least 3 months	Dose 2 to 3	At least 4 weeks
			Dose 3 to 4	At least 3 months	Dose 3 to 4	At least 3 months
			Dose 4 to 5	At least 4 months	Dose 4 to 5	At least 4 months

\*Complete the primary series with same product. If the vaccine product previously administered cannot be administered or is no longer available, any age appropriate mRNA COVID-19 vaccine product may be administered up to 30 days after the first dose. Any COVID-19 vaccine product (age appropriate) may be administered for a booster dose 18 weeks or more after the same product used for the primary series.  
<sup>1</sup> Persons with a recent SARS-CoV-2 infection may consider obtaining a primary series or booster dose by 3 months from symptom onset or positive test if infection was asymptomatic.  
<sup>2</sup> Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 3 weeks. A 6-week interval may be optimal for people who are not regularly or severely immunocompromised and age 16-17 years, especially for males ages 15-16 years.  
 06/17/2022

# Pfizer-BioNTech COVID-19 Vaccine Products



**Product for ages  
6 mons – 4 years**



**Product for ages  
5–11 years**




**Product for ages  
12 years and older**

	Product for ages 6 mons – 4 years	Product for ages 5–11 years	Product for ages 12 years and older
<b>Authorized for ages</b>	6 months–4 years	5–11 years	12 years and older
<b>Vial cap color</b>	Maroon	Orange	Gray
<b>Dose (mRNA concentration)</b>	3 mcg	10 mcg	30 mcg
<b>Injection volume</b>	0.2 mL	0.2 mL	0.3 mL
<b>Dilution required</b>	Yes—2.2 mL	Yes—1.3 mL	No
<b>Doses per vial</b>	10 (after dilution)	10 (after dilution)	6

# Pfizer-BioNTech COVID-19 Vaccine Product for Ages 6 Months – 4 Years Label

Vaccine may be discarded **12 hours** after dilution rather than **6 hours**.



Vial label states Age 2y to <5y but can be used in children ages 6 months–4 years.

# Moderna COVID-19 Vaccine Products

Authorized Age group		<b>6 months–5 years</b> (primary series)		<ul style="list-style-type: none"> <li>• <b>6–11 years</b> (primary series)</li> <li>• <b>18 years and older</b> (booster doses)</li> </ul>		<ul style="list-style-type: none"> <li>• <b>12 years and older</b> (primary series)</li> <li>• <b>18 years and older</b> (booster doses)</li> </ul>
<b>Vial cap color</b>	Dark blue	Dark blue	Red			
<b>Label border color</b>	Magenta	Purple	Light blue			
<b>Dose (mRNA concentration)</b>	25 mcg	50 mcg	100 mcg (primary, age 12+); 50mcg (booster, age 18+)			
<b>Injection volume volume</b>	0.25 mL	0.5 mL	0.5 mL (primary, age 12+); 0.25mL (booster, age 18+)			
<b>Dilution required</b>	No	No	No			
<b>Doses per vial</b>	10	5	Maximum of 11			

# Moderna COVID-19 Vaccine Product for Ages 6-11 Years



703595



STORE FROZEN between  
-50° to -15°C (-58° to 5°F).  
Protect from light. No preservative.  
After first use, hold at 2° to 25°C  
(36° to 77°F). Discard after 12 hours.

Record date/time of first use: \_\_\_\_\_

Scan here for FDA-authorized Fact Sheet  
for dosage and administration,  
and product expiration dates, or visit  
[www.modernatx.com/covid19vaccine-eua/](http://www.modernatx.com/covid19vaccine-eua/)

Mfd. for: Moderna US, Inc.,  
Cambridge, MA 02139

## Moderna COVID-19 Vaccine

Suspension for  
Intramuscular Injection  
For use under  
Emergency Use Authorization

NDC 80777-275-05

**BOOSTER DOSES ONLY**



2.5 mL Multi-Dose Vial  
**Booster Dose: 0.5 mL**



LOT

Labeled for “**BOOSTER DOSES ONLY**” but is authorized for:

- Primary doses in children ages 6–11 years
- Booster doses in adults ages 18 years and older

# Product Resources

- Storage, handling, preparation, and administration job aids by product:
  - <https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html>
- Pfizer-BioNTech label infographic:
  - <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/infant-label-info.pdf>
- Moderna label infographic:
  - <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/Moderna-children-updated-label-iinfo-508.pdf>
- At-a-glance job aids
  - Pfizer-BioNTech:
    - <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/vaccine-at-a-glance.pdf>
  - Moderna:
    - <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/vaccine-at-a-glance.pdf>




# Vaccine Dosage: CDC's Recommendation

- **CDC'S recommendation:** Children should receive the age-appropriate vaccine product and follow the schedule based on their age **on the day of vaccination**, regardless of their size or weight.
- If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine dosage for the older age group for all subsequent doses.
- FDA authorization allows for dosing options for certain age transitions. If these options occur, they are not considered errors and the doses “count”.

# FDA Allowance for Moderna Age 5 to 6 Years

Children who will turn from age 5 years to 6 years between doses in the primary series to receive, for any primary dose: (1) the Moderna COVID-19 Vaccine product authorized for children ages 6 months–5 years or (2) the Moderna COVID-19 Vaccine product authorized for children ages 6–11 years.



## **Dose 1 (Age 5):**

0.25 mL (25 mcg) of the product for ages  
6 months–5 years or  
0.50 mL (50 mcg) of the product for  
ages 6–11 years


## **Dose 2 (Age 6):**

0.25 mL (25 mcg) of the product for ages  
6 months–5 years or  
0.50 mL (50 mcg) of the product for ages  
6–11 years



# FDA Allowance for Moderna Age 11 to 12 Years

Children who will turn from age 11 years to 12 years between doses in the primary series to receive, for any primary dose: (1) the Moderna COVID-19 Vaccine product authorized for children ages 6–11 years or (2) the Moderna COVID-19 Vaccine product authorized for people ages 12 years and older.



## **Dose 1 (Age 11):**

0.50 mL (50 mcg) of the product for ages  
6–11 years

0.50 mL (100mcg) of the product for ages  
12 years and older


## **Dose 2 (Age 12):**

0.50 mL (50 mcg) of the product for  
ages 6–11 years

0.50 mL (100mcg) of the product for  
ages 12 years and older


# FDA Allowance for Pfizer-BioNTech Age 4 to 5 Years

**Scenario 1:** A 2-dose primary series using the product for people ages 5–11 years (orange cap)



# FDA Allowance for Pfizer-BioNTech Age 4 to 5 Years

**Scenario 2:** A 3-dose primary series initiated with the product for ages 6 months–4 years. Dose 2 and 3 may be with: the product for ages 6 months–4 years or the product for ages 5–11 years.



**Dose 1 (Age 4):**

0.2 mL (3 mcg) of the product for ages 6 months–4 years

**Dose 2 (Age 4 or 5):**

0.2 mL (3 mcg) of the product for ages 6 months–4 years, or  
0.2 mL (10 mcg) of the product for ages 5–11 years

**Dose 3 (Age 5):**

0.2 mL (3 mcg) of the product for ages 6 months–4 years, or  
0.2 mL (10 mcg) of the product for ages 5–11 years

# Aging up Resources

- Moderna:  
<https://www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf>
- Pfizer-BioNTech:  
<https://www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf>

The image displays two CDC informational slides. The top slide is for the Pfizer-BioNTech COVID-19 Vaccine, titled 'Pfizer-BioNTech COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group'. It states that CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on the day of vaccination. It also notes that if a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster doses, they should receive the vaccine product and dosage for the older age group for all subsequent doses. The bottom slide is for the Moderna COVID-19 Vaccine, titled 'Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group'. It also states that CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on the day of vaccination. It notes that if a person moves from a younger age group to an older age group during the primary series, they should receive the vaccine product and dosage for the older age group for all subsequent doses. The slide includes a section for 'Children who turn from age 5 to age 6 years' with a diagram showing Dose 1 (Age 5: 0.25 mL, 25 mcg) and Dose 2 (Age 6: 0.50 mL, 50 mcg) separated by 4-8 weeks. It also includes a section for 'Acceptable' dosing, stating that if the following dosing occurs, it is NOT considered an error and the primary series is considered complete. The acceptable dosing options are: 0.25 mL, 25 mcg for ages 6 months-5 years (dark blue cap/magenta label border), or 0.50 mL, 50 mcg for ages 6-11 years (dark blue cap/purple label border). A diagram shows Dose 1 (Age 5) and Dose 2 (Age 6) separated by 4-8 weeks.

# Interchangeability

- COVID-19 vaccines are not interchangeable.
- The same mRNA vaccine product should be used for all doses of the primary series.
- In exceptional situations in which the mRNA vaccine product administered for a previous dose(s) of the primary series cannot be determined or is not available, either age-appropriate available mRNA COVID-19 vaccine product may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 primary vaccination series.

# Mixed Series for Children Ages 6 Months – 4 Years

- Children ages 6 months–4 years who receive different mRNA products for the first 2 doses of an mRNA COVID-19 vaccine series should receive a third dose of either mRNA vaccine 8 weeks after the second dose to complete the 3-dose primary series.

# Mixed Series for Children Ages 6 Months – 4 Years

## ■ Scenario 1:



### Dose 1:

0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years

4-8 weeks



### Dose 2:

0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years

8 weeks



--or--



### Dose 3:

0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years  
--or--  
0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years

# Mixed Series for Children Ages 6 Months – 4 Years



## Dose 1:

0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years

## Dose 2:

0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years

## Dose 3:

0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years

--or--

0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years



# Preventing Vaccine Administration Errors

- Clinical guidance for errors: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#appendix-c>
- Handout: <https://www.cdc.gov/vaccines/hcp/admin/downloads/vaccine-administration-preventing-errors.pdf>

**YOU CALL THE SHOTS** Vaccine Administration: Preventing Vaccine Administration Errors

A vaccine administration error is any preventable event that may cause or lead to inappropriate medication use or patient harm.<sup>1</sup> Vaccine administration errors can have many consequences, including inadequate immunological protection, possible injury to the patient, cost, inconvenience, and reduced confidence in the health care delivery system. Take preventive actions to avoid vaccine administration errors and establish an environment that values reporting and investigating errors as part of risk management and quality improvement.

Vaccine administration errors may be due to causes such as:

- Insufficient staff training
- Distraction
- Changes in recommendations
- Lack of standardized protocols
- Patient misidentification
- Using nonstandard or error-prone abbreviations
- Easily misidentified products (e.g., DTaP, DT, Tdap, Td)

If an error occurs, determine how it occurred and take the appropriate actions to put strategies in place to prevent it from happening in the future. The following table outlines common vaccine administration errors and possible preventive actions you can take to avoid errors.

Error(s)	Possible Preventive Actions
Wrong vaccine, route, site, or dosage (amount) or improperly prepared.	<ul style="list-style-type: none"><li>Circle important information on the packaging to emphasize the difference between the vaccines.</li><li>Include the brand name with the vaccine abbreviation whenever possible (e.g., PCV13 [Pneumovax 13] in orders, medical screens, etc).</li><li>Separate vaccines into bins or other containers according to type and formulation. Use color-coded identification labels on vaccine storage containers.</li><li>Store look-alike vaccines in different areas of the storage unit (e.g., pediatric and adult formulations of the same vaccine on different shelves in the unit).</li><li>Do not list vaccines with look-alike names sequentially on computer screens, order forms, or medical records, if possible.</li><li>Consider using "name alert" or "look-alike" stickers on packaging and areas where these vaccines are stored.</li><li>Consider purchasing products with look-alike packaging from different manufacturers, if possible.</li><li>Establish "Do NOT Disturb" or no-interruption areas or times when vaccines are being prepared or administered.</li><li>Prepare vaccine for one patient at a time. Once prepared, label the syringe with vaccine name.</li><li>Do not administer vaccines prepared by someone else.</li><li>Triple-check work before administering a vaccine and ask another staff member to check.</li><li>Keep reference materials on recommended sites, routes, and needle lengths for each vaccine used in your facility in the medication preparation area.</li><li>Clearly identify diluents if the manufacturer's label could mislead staff into believing the diluent is the vaccine itself.</li><li>Integrate vaccine administration training into orientation and other appropriate education requirements.</li><li>Provide education when new products are added to inventory or recommendations are updated.</li><li>Use standing orders, if appropriate.</li></ul>

1. National Coordinating Council for Medication Error Reporting and Prevention. <https://www.nccmerpit.org/about/medication-errors>. 08/01/2007. CS 112001-4

WVRS website at <https://vaxer.hhs.gov/reportevent.html>

\* At this time, COVID-19 vaccination has additional WRS reporting requirements, including required reporting of vaccine administration errors. Please see <https://www.cdc.gov/media/releases/2021/s1112-covid19-vax-wrs.html> for more information.

08/01/2021 CS 112001-4

**Preventive Actions**

- Identify before administering vaccines.
- The importance of avoiding unnecessary distractions or interruptions when staff is vaccine.
- Administer vaccines to one patient at a time. If more than one patient needs vaccines (clinical encounter (e.g., parent with two children), assign different providers to each vaccine. Alternatively, bring only one patient's vaccines into the treatment area at a time, note and patient name.
- Use abbreviations to document vaccine administration (e.g., use intraneural route not the intraneural route—not IN, which is easily confused with IM).
- Use abbreviations.
- Use abbreviations of look-alike names or generic abbreviations on computer screens, if possible.
- Use storage and handling training based on manufacturer guidance and/or
- Use those with the earliest expiration dates are in the front of the storage unit. Use
- Vaccines/diluents from storage units and areas where viable vaccines are stored.
- Respond to improper temperatures and contact the state or local immunization the vaccine manufacturer.
- Identify, if appropriate.
- Use to obtain a complete vaccination history using the immunization information previous medical records, and personal vaccination records.
- Use administration training, including timing and spacing of vaccines, into orientation appropriate education requirements.
- Use for infants, schedule immunization visits after the birthday.
- Use immunization schedules for children and adults that staff can quickly reference in clinical situations may be prescribed and administered.
- Use sheets for timing and spacing in your medication preparation area. CDC has vaccine box for DTaP, Tdap, Hib, PCV13, and polio vaccines to assist health care personnel in catch-up schedule for children.
- Use and patients on how important it is for them to maintain immunization records.
- Use to report vaccine administration errors to WRS.\* To file an electronic report, please see the

# Interim Clinical Considerations

- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States:

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>

- FAQs for the Interim Clinical Considerations:

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/faq.html>

The screenshot shows the CDC website page for 'Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States'. The page is part of the 'Vaccines & Immunizations' section. It features a navigation menu on the left with categories like 'COVID-19 Vaccination', 'Product Info by U.S. Vaccine', 'Interim Clinical Considerations', 'Use of COVID-19 Vaccines in the U.S.', 'FAQs for the Interim Clinical Considerations', 'Managing Anaphylaxis', 'Myocarditis and Pericarditis Considerations', 'Lab Tests After Severe Allergic Reactions', 'Clinical Care', 'Provider Requirements and Support', 'Training and Education', 'Vaccine Recipient Education', 'Health Departments', 'Planning & Partnerships', and 'Vaccine Effectiveness Research'. The main content area includes a title, a summary of recent changes (last updated June 24, 2022), a list of reference materials, and a 'Get Email Updates' section. The 'Reference Materials' section lists several documents, including a 'Summary Document for Interim Clinical Considerations', an 'Interim COVID-19 Immunization Schedule', an 'At-A-Glance COVID-19 Vaccination Schedule (NEW 6/24/2022)', a 'Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group (NEW 6/24/2022)', and a 'Pfizer-BioNTech for Children who Transition from a Younger to Older Age Group (NEW 6/24/2022)'. The 'Get Email Updates' section includes a text box for email updates, a 'What's this?' link, and a 'Get Email Updates' button. Below the main content, there is a section titled 'About the clinical considerations' with expandable sections for 'Key points' and 'Purpose'.

# Clinical Resources

US COVID-19 Vaccine  
Product Information:  
<https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html>

The screenshot displays the CDC's 'Vaccines & Immunizations' page for COVID-19. The page is titled 'U.S. COVID-19 Vaccine Product Information' and includes a navigation menu on the left with categories like 'Product Info by U.S. Vaccine', 'EUA', 'EUI', and 'FAQs for Healthcare Professionals'. The main content area features a search bar, a language selector for 'Español', and three main sections: 'Pfizer-BioNTech', 'Moderna', and 'Janssen/J&J'. Each section contains a brief description and a link to further resources. For example, the Pfizer-BioNTech section links to the 'Interim COVID-19 Immunization Schedule for Ages 5+', and the Janssen/J&J section links to the 'Prevaccination Screening Form COVID-19 Prevaccination Guidelines'.

# Miscellaneous

- No shipments on 4<sup>th</sup> of July
- Pfizer-BioNTech expiration look up tool available in July
- Moderna 6-11 ancillary kits – packaged at 140 quantity with 1” needles
- Alternative languages not yet available for EUA Fact Sheets
- Novavax
  - Only 3 million purchased under contract
  - 100 minimum dose quantity – 10 dose vials/10 vials in box
  - 2 dose series
  - Anticipated to be available in August

# Questions?

## Maine Immunization Program

Education: [ImmunizeMe.DHHS@Maine.gov](mailto:ImmunizeMe.DHHS@Maine.gov)

ImmPact: [ImmPact.Support@Maine.gov](mailto:ImmPact.Support@Maine.gov)

MIP Website: [www.ImmunizeME.org](http://www.ImmunizeME.org)

[www.bravelikeme.com](http://www.bravelikeme.com)

